Trial Profile
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sapanisertib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 17 Oct 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 24 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2020.
- 29 Jan 2020 Planned primary completion date changed from 31 Dec 2019 to 30 Jun 2020.